AR and prostate carcinoma: The therapeutic landscape of prostate cancer has changed dramatically in the last decade, with the introduction of androgen receptor-targeted therapies, including abiraterone acetate and enzalutamide4, and upfront combination treatments5,6, which have improved patient outcomes.